目的 探讨金水宝胶囊联合阿魏酸哌嗪治疗慢性肾小球肾炎的临床疗效。方法 选取2021年7月—2023年7月眉山市人民医院收治的148例慢性肾小球肾炎患者，采用随机数字表法将148例慢性肾小球肾炎患者分为对照组（74例）和治疗组（74例）。对照组患者口服阿魏酸哌嗪片，100 mg/次，3次/d。治疗组患者在对照组的治疗基础上口服金水宝胶囊，6粒/次，3次/d。两组均连续治疗3个月。观察两组患者的疗效和中医症状改善时间，比较两组治疗前后血液高凝状态指标、肾功能指标。结果 治疗后，治疗组的总有效率是94.59%，显著高于对照组的83.78%（P＜0.05）。与对照组比较，治疗组疲倦乏力、颜面浮肿、腰脊酸痛改善时间更短（P＜0.05）。治疗3个月后，两组纤维蛋白原、D-二聚体、血栓素B2（TXB2）水平均较同组治疗前显著降低（P＜0.05）；与对照组比较，治疗3个月后治疗组患者纤维蛋白原、D-二聚体、TXB2水平更低（P＜0.05）。治疗后，两组胱抑素C（CysC）、视黄醇结合蛋白（RBP）、尿素氮、肌酐水平均降低，而肾小球滤过率（eGFR）水平升高（P＜0.05）；与对照组比较，治疗后治疗组患者CysC、RBP、尿素氮、肌酐水平更低，eGFR水平更高（P＜0.05）。结论 金水宝胶囊联合阿魏酸哌嗪治疗慢性肾小球肾炎可获得较为理想的治疗效果，对患者血液高凝状态以及肾功能均有明显的改善作用，且无明显不良反应，安全性较高。

Objective To explore the therapeutic effect of Jinshuibao Capsules combined with piperazine ferulate in treatment of chronic glomerulonephritis. Methods A total of 148 patients with chronic glomerulonephritis admitted to Meishan City People’s Hospital from July 2021 to July 2023 were selected, and 148 patients with chronic glomerulonephritis were divided into control group (74 cases) and treatment group (74 cases) by random number table method. Patients in the control group were po administered with Piperazine Ferulate Tablets, 100 mg/time, three times daily. Patients in the treatment group were po administered with Jinshuibao Capsules on the basis of the control group, 6 grains/time, three times daily. Both groups were treated continuously for 3 months. The curative effect and the improvement time of TCM symptoms in two groups were observed, and the indexes of blood hypercoagulability and renal function before and after treatment were compared. Results After treatment, the total effective rate of the treatment group was 94.59%, which was significantly higher than that of the control group (83.78%, P < 0.05). Compared with the control group, the improvement time of fatigue, facial edema and lumbar soreness in the treatment group was shorter (P < 0.05). After 3 months of treatment, the levels of fibrinogen, D-dimer, and thromboxane B2 (TXB2) in 2 groups were significantly decreased compared with before treatment (P < 0.05). Compared with the control group, the levels of fibrinogen, D-dimer, and TXB2 in treatment group were lower after 3 months of treatment (P < 0.05). After treatment, the levels of cystatin C (CysC), retinol-binding protein (RBP), urea nitrogen and creatinine were decreased in both groups, but the levels of glomerular filtration rate (eGFR) were increased (P < 0.05). Compared with the control group, the levels of CysC, RBP, urea nitrogen, and creatinine in treatment group were lower after treatment, and the levels of eGFR were higher (P < 0.05). Conclusion Jinshuibao Capsules combined with piperazine ferulate achieves ideal therapeutic effects in treatment of chronic glomerulonephritis, and has a significant improvement effect on blood hypercoagulability and renal function in patients, and there are no significant adverse reactions with high safety.

R983

四川省科技计划项目（19YYJC0256）